In end-of-life care, deprescribing practices may vary considerably from one practitioner to the next, although most published frameworks for evaluating medication appropriateness in advanced illness consider three key principles (1) patient and caregiver goals, (2) remaining life expectancy (LE), and (3) medication time to benefit (TTB). The objective of this article is to provide clinicians with a structured, consistent approach for deprescribing that does not replace clinical judgment or the preferences of patients and their families but enhances it through clinical data. The emphasis will be on the time component of published models, including how to estimate remaining LE and medication TTB. Through case examples of two new hospice admissions, LE and TTB will be estimated and applied to deprescribing decisions. This time-centric approach may satisfy the palliative and hospice clinicians' desire for clear clinical justification for medication discontinuation while at the same time providing a strategy for communicating deprescribing rationale to patients and families.
Get full access to this article
View all access options for this article.
References
1.
ZuegerP, HolmesHM, CalipGS, et al.: Medicare part D use of older Medicare beneficiaries admitted to hospice. J Am Geriatr Soc, 2018; 66: 937–944.
2.
ScottIA, HilmerSN, ReeveE, et al.: Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med, 2015; 175: 827–834.
3.
LeeSJ, KimCM: Individualizing prevention for older adults. J Am Geriatr Soc, 2018; 66: 229–234.
4.
O'BrienCP: Withdrawing medication: Managing medical comorbidities near the end of life. Can Fam Physician, 2011; 57: 304–307.
5.
StevensonJ, AbernethyAP, MillerC, CurrowDC: Managing comorbidities in patients at the end-of-life. BMJ, 2004; 329: 909–912.
6.
HolmesHM, HayleyDC, AlexanderGC, SachsGA: Reconsidering medication appropriateness for patients late in life. Arch Intern Med, 2006; 166: 605–609.
7.
LeeSJ, LeipzigRM, WalterLC: “When will it help?” incorporating lagtime to benefit into prevention decisions for older adults. JAMA, 2013; 310: 2609–2610.
8.
CurrowDC, AbernethyAP: Frameworks for approaching prescribing at the end of life. Arch Intern Med, 2006; 166: 2404.
9.
Lindsay J, Dooley M, Martin J, et al.: The development and evaluation of an oncological palliative care deprescribing guideline: The ‘oncpal deprescribing guideline.’ Support Care Cancer 2015;23:71–78.
10.
HolmesHM, MinLC, YeeM, et al.: Rationalizing deprescribing for older adults with multimorbidity: Considering time to benefit. Drugs Aging, 2013; 30: 655–666.
11.
FrankC, WeirE: Deprescribing for older adults. CMAJ, 2014; 186: 1369–1376.
Social Security Administration. Actuarial life table: period life table, 2017. https://www.ssa.gov/oact/STATS/table 4c6.html (Last accessed May28, 2020).
AndersonF, DowningGM, HillJ, et al.: Palliative performance scale (PPS): A new tool. J Palliat Care, 1996; 12: 5–11.
23.
HeadB, RitchieCS, SmootTM: Prognostication in hospice care: Can the palliative performance scale help?. J Palliat Med, 2005; 8: 492–502.
24.
WeissmanD: Determining prognosis in advanced cancer #13. J Palliat Med, 2003; 6: 433–434.
25.
LuchinsDJ, HanrahanP, MurphyK: Criteria for enrolling dementia patients in hospice. J Am Geriatr Soc, 1997; 45: 1054–1059.
26.
VolicerL: Hospice care for dementia patients. J Am Geriatr Soc, 1997; 1147–1149.
27.
McPhersonA, McPhersonML: Deprescribing: Right-sizing medication regimens to optimize outcomes in palliative care. Curr Geri Rep, 2019; 8: 21–30.
28.
GrundySM, StoneNJ, BaileyAL, et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol, 2019; 73: e285–e350.
29.
WilliamsonJD, SupianoMA, ApplegateWB, et al.: Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/ = 75 years: A randomized clinical trial. JAMA, 2016; 315:2673–2682.
30.
van de GlindEM, WillemsHC, EslamiS, et al.: Estimating the time to benefit for preventive drugs with the statistical process control method: An example with Alendronate. Drugs Aging, 2016; 33:347–353.
31.
Hanora LavanA, GallagherP, ParsonsC, et al.: STOPPFrail (screening tool of older persons prescriptons in frail adults with limited life expectancy): Consensus validation. Age Ageing, 2017; 46:600–607.
McCoubrieR, JeffreyD, PatonC, et al.: Managing diabetes mellitus in patients with advanced cancer: A case note audit and guidelines. Eur J Cancer Care, 2005; 14:244–248.
35.
LeeS.Jacobson MA, Johnston CB: Improving diabetes care for hospice patients. Am J Hosp Palliat Care, 2016; 33:517–519.
36.
American Diabetes Association: Older adults: Standards of medical care in diabetes 2020. Diabetes Care, 2020; 43(Suppl 1):S152–S162.
KutnerJ, BlatchfordP, TaylorD, et al.: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med, 2015; 175: 691–700.
39.
HeeschenC, HammC, LaufsU: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 2002; 105:1446–1452.
40.
PowersW, RabinsteinA, AckersonT, et al.: 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2018; 49:e46–e99.
41.
TranN, DiScalaS, DeepakM, et al.: Discontinuation of statins at the end of life #322. J Palliat Med, 2017; 20:199–200.
42.
DavisM, BehmB: Is it safe to discontinue statins? Does stopping statins improve quality of life: Yes and no. J Palliat Med, 2018; 21:281–282.
43.
VollrathA, SinclairC, HallenbackJ: Discontinuing cardiovascular medications at the end of life: Lipid-lowering agents. J Palliat Med, 2005; 8:876–881.
44.
LaRosa JC, Deedwania PC, Shepherd J, et al.: Comparison of 80 mg versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the treating to new targets [TNT] trial) Am J Cardiol 2010;105:283–287.
45.
CannonCP, BraunwaldE, McCabe, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350:1495–1504.
46.
BarterPJ, WatersDD: Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol, 2018; 12:857–862.
47.
SchwartzGG, OlssonAG, EzekowitzMD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA, 2001; 285:1711–1718.
48.
Bibbins-DomingoK: Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2016; 164:836–845.
49.
BowmanL, MafhamM, WallendszusK, et al.: Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med, 2018; 379:1529–1539.
50.
GazianoJM, BrotonsC, CoppolecchiaR, et al.: Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomized, double-blind, placebo-controlled trial. Lancet, 2018; 392:1036–1046.
51.
BowmanL, MafhamM, WallendszusK, et al.: Supplement to The ASCEND Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med [Epub ahead of print; DOI: 10.1056/nejmoa1804988].
52.
ArnettDK, BlumenthalRS, AlbertMA, et al.: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on clinic practice guidelines. Circulation, 2019; 140:e596–e646.
53.
Antiplatelet Trialists'. Collaboration. Collaborative overview of randomized trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994; 308:81–106.
54.
Antiplatelet Trialist's Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002; 324:71–86.
55.
Antiplatelet Trialist's Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. Lancet, 2009; 373:1849–1860.
56.
YusufS, ZhaoF, MehtaSR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345:494–502.
57.
MehtaSR, YusufS, PetersRJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 2001; 358:527–533.
58.
BittlJA, BaberU, BradleySM, et al.: Duration of dual antiplatelet therapy: A systemic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2016; 68:1116.
59.
UrbanP, MeredithIT, AbizaidA, et al.: Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med, 2015; 373:2038.
60.
AriottiS, AdamoM, CostaF, et al.: Is Bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv, 2016; 9:426.
61.
LevineG, BatesR, BittlJ, et al.: 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol, 2016; 68:1082–1115.
JohnsonM, HoggK, BeattieJ: Heart Failure: From Advanced Disease to Bereavement. Oxford, UK: Oxford University Press, 2012.
64.
PonikowskiP, VoorsA, AnkerS, et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure—Web Addenda. Eur J Heart Fail, 2016; 18:891–975.
65.
YancyCW, JessupM, Bozkurt, et al.: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 2013; 128:e240–e327.
66.
PeixotoAJ: Acute severe hypertension. N Engl J Med, 2019; 381:1843–1852.
67.
ConnollySJ, LaupacisA, GentM: Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol, 1991; 18:349–355.
68.
European Atrial Fibrillation Trial (EAFT) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, 1993; 342:1255–1262.
69.
ConnollySJ, EikelboomJ, JoynerC, et al.: Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364:806–817.
70.
JanuaryCT, WannS, AlpertJ, et al.: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol, 2014; 64:e17.
71.
LipG, BanerjeeA, BorianiG, et al.: Antithrombotic therapy for atrial fibrillation CHEST guideline and expert panel report. Chest, 2018; 154:1121–1201.
72.
FullerR, DudleyN, BlacktopJ: Older people's understanding of cumulative risks when provided with annual stroke risk information. Postgrad Med J, 2004; 80:677–678.
73.
DouketisJD, SpyropoulosAC, SpencerFA: Perioperative management of antithrombotic therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141(2Suppl):e326S–e350S.
74.
Stroke prevention in atrial fibrillation study. Final results. Circulation, 1991; 84:527–539.
American Psychiatric Association (APA). Guideline watch: practice guideline for the treatment of patients with Alzheimer's disease and other dementias (October 2014). http://psychiatryonline.org/guidelines (Last accessed July3, 2020).
77.
MitchellSL, TenoJM, KielyDK, et al.: The clinical course of advanced dementia. N Engl J Med, 2009; 361:1529–1538.
78.
FarlowMR, SallowayS, TariotPN, et al.: Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clin Ther, 2010; 32:1234–1251.
79.
FarlowMR, GrossbergGT, SadowskyCH, et al.: A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther, 2013; 19:745–752.
80.
GeijtemanE, DeesM, TemplemanM, et al.: Understanding the continuation of potentially inappropriate medications at the end of life: Perspectives from individuals and their relatives and physicians. J Am Geriatr Soc, 2016; 64:2602–2604.
